整合最佳实践以改善复发/难治性多发性骨髓瘤的治疗结果
Integrating Best Practices to Improve Outcomes in Relapsed/Refractory Multiple Myeloma.
作者信息
Pierre Amy E, Richter Joshua
机构信息
Memorial Sloan Kettering Cancer Center, New York, New York.
Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York, New York.
出版信息
J Adv Pract Oncol. 2020 Apr;11(3):306-311. doi: 10.6004/jadpro.2020.11.3.18. Epub 2020 Apr 1.
Abstract
Amy E. Pierre, MSN, ANP-BC, and Joshua Richter, MD, break down the approved and emerging treatment options for relapsed/refractory multiple myeloma, including mechanisms of action, supporting clinical data, and associated adverse events, and discuss best practices for selecting and sequencing therapy.
摘要
艾米·E·皮埃尔，护理学硕士，成人护理执业医师 - 认证，以及约书亚·里克特，医学博士，剖析了复发/难治性多发性骨髓瘤的获批治疗方案和新兴治疗方案，包括作用机制、支持性临床数据及相关不良事件，并讨论了治疗选择和排序的最佳实践。
相似文献
1
Integrating Best Practices to Improve Outcomes in Relapsed/Refractory Multiple Myeloma.整合最佳实践以改善复发/难治性多发性骨髓瘤的治疗结果
J Adv Pract Oncol. 2020 Apr;11(3):306-311. doi: 10.6004/jadpro.2020.11.3.18. Epub 2020 Apr 1.
2
2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Hematologic Malignancies.2019年美国临床肿瘤学会年会高级从业者亮点：血液系统恶性肿瘤
J Adv Pract Oncol. 2019 Aug;10(6):601-609. doi: 10.6004/jadpro.2019.10.6.10. Epub 2019 Aug 1.
3
The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies.复发/难治性多发性骨髓瘤治疗的未来：新兴药物和新型治疗策略。
Semin Hematol. 2012 Jul;49 Suppl 1:S33-46. doi: 10.1053/j.seminhematol.2012.05.004.
4
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
5
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.CUDC-907（一种新型口服组蛋白去乙酰化酶（HDAC）和磷脂酰肌醇-3激酶（PI3K）双重抑制剂）在复发或难治性淋巴瘤或多发性骨髓瘤患者中的安全性、耐受性及初步活性：一项开放标签、剂量递增的1期试验。
Lancet Oncol. 2016 May;17(5):622-31. doi: 10.1016/S1470-2045(15)00584-7. Epub 2016 Mar 31.
6
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.复发或难治性多发性骨髓瘤患者中人性化抗CD19和抗BCMA嵌合抗原受体T细胞的联合应用：一项单臂2期试验
Lancet Haematol. 2019 Oct;6(10):e521-e529. doi: 10.1016/S2352-3026(19)30115-2. Epub 2019 Aug 1.
7
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.每周一次与每周两次卡非佐米给药治疗复发和难治性多发性骨髓瘤患者（A.R.R.O.W.）：一项随机、3 期研究的中期分析结果。
Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1.
8
Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.帕比司他治疗复发/难治性多发性骨髓瘤相关不良事件的发生率及管理
J Oncol Pharm Pract. 2019 Apr;25(3):613-622. doi: 10.1177/1078155218788706. Epub 2018 Jul 31.
9
[Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].基于硼替佐米的复发或难治性多发性骨髓瘤联合疗法
Zhonghua Nei Ke Za Zhi. 2008 Feb;47(2):102-6.
10
Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.泊马度胺：复发和难治性多发性骨髓瘤的治疗药物。
Drugs. 2017 Nov;77(17):1897-1908. doi: 10.1007/s40265-017-0833-y.
引用本文的文献
1
Tackling Mantle Cell Lymphoma in Europe.欧洲应对套细胞淋巴瘤
Healthcare (Basel). 2022 Sep 3;10(9):1682. doi: 10.3390/healthcare10091682.
本文引用的文献
1
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.口服塞利尼索联合地塞米松治疗三药难治性多发性骨髓瘤。
N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.
2
Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma.多发性骨髓瘤患者免疫调节药物相关血栓形成风险评估模型的推导和验证。
J Natl Compr Canc Netw. 2019 Jul 1;17(7):840-847. doi: 10.6004/jnccn.2018.7273.
3
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
4
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.
5
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.来那度胺、伊沙佐米和地塞米松联合治疗多发性骨髓瘤。
N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.
6
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.随机2期研究：埃罗妥珠单抗联合硼替佐米/地塞米松对比硼替佐米/地塞米松用于复发/难治性多发性骨髓瘤
Blood. 2016 Jun 9;127(23):2833-40. doi: 10.1182/blood-2016-01-694604. Epub 2016 Apr 18.
7
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.卡非佐米和地塞米松与硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者的比较（ENDEAVOR）：一项随机、3 期、开放标签、多中心研究。
Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5.
8
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.帕比司他联合硼替佐米和地塞米松对比硼替佐米和地塞米松联合安慰剂治疗复发或复发难治性多发性骨髓瘤患者：一项多中心、随机、双盲的 3 期临床试验。
Lancet Oncol. 2014 Oct;15(11):1195-206. doi: 10.1016/S1470-2045(14)70440-1. Epub 2014 Sep 18.
Zotero 插件